Inactive Instrument

News Summit Therapeutics plc London S.E.

Equities

GB00BN40HZ01

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors	Jun. 27	BU
Summit Therapeutics Inc. Appoints Jeff Huber to Its Board of Directors	Jun. 27	CI
Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Senior Vice President and Chief Business Officer	Jun. 24	CI
Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Chief Financial Officer	Jun. 24	CI
Summit Therapeutics Inc. announced that it has received $199.999998 million in funding from Baker Bros. Advisors LP	Jun. 17	CI
Summit Therapeutics Inc. Announces Resignation of Ujwala Mahatme as Member of its Board	Jun. 13	CI
Sector Update: Health Care Stocks Steady Premarket Monday	Jun. 03	MT
Stifel Adjusts Summit Therapeutics Price Target to $14 From $8, Maintains Buy Rating	Jun. 03	MT
Transcript : Summit Therapeutics Inc. - Special Call	Jun. 03
Summit Therapeutics Generates $200 Million Through Share Sale; Expand License Territories for Ivonescimab	Jun. 03	MT
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab	Jun. 03	BU
Summit Therapeutics Inc. Expands License Territories for Ivonescimab	Jun. 03	CI
Summit Therapeutics Inc. announced that it expects to receive $199.999998 million in funding from Baker Bros. Advisors LP	Jun. 02	CI
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA	Jun. 01	BU
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy	May. 31	BU
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday	May. 31	MT
Wall Street Set to Open Modestly Higher Friday as Key Inflation Data Meets Expectations	May. 31	MT
Sector Update: Health Care	May. 31	MT
US Futures Trend Modestly Lower Pre-Bell Friday as Investors Await Key Inflation Report	May. 31	MT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 30	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Summit Therapeutics plc London S.E.

Equities

GB00BN40HZ01

Summary

Filters